September 19, 2017 7:05pm

… For its cannons to fire and repel the downside takers

 

Pirates are needed to drive back the selling armadas; we need more buccaneers out there!

 

Pre-open indications: 6 hits and 1 miss (by pennies)

Out and about: Applied Genetic Technologies (AGTC) tries to see some upside and fails closing flat at $3.75 with 368.3 K shares traded <3 month average = 218.36 K shares>. Why CEO Washer hasn’t or doesn’t put her own money where her focus should have been …?

 

I answer one question, in which company should investors commit and keep their money. In the grip of rotating cycles and disparaging trends, what is the price of sector knowledge – a subscription!  


 

Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s newsletter “the sector … anticipates vulnerability in a sector of coincidental risk. It has been said that as September closes and Q3 ends, volatility jumps as many get out at highs to be ahead of the end of the quarter’s unwinding.”

The Fed meeting has started and is not expected to raise rates following its meeting. However, many market participants believe the central bank will announce the unwinding of its massive $4.5 trillion portfolio.

 

Just because sector stock keeps getting cheaper doesn't make them more attractive – just better to PLAY up and down with!

I believe this sector complacency defines sentiment, which is between negative and bad, understandable in the context of a sector that typically reverts in its performance!

Cell, stem and gene therapy companies moved to the downside on what – an algorithmic computation.

 

 

Some of MY working trend lines or indications:

… The greatest volume to the downside:  MDXG, SGMO, VSTM, JUNO and BLCM

… Upside volume was weighted to:  CAPR, IMUC, NWBO, ATHX and KITE

… Biggest $ downside:  BLUE, JUNO, RGNX, XON and MDXG

… Largest $ upside:  ONCE, CAPR, KITE, STML and ATHX

… Flat:  VCEL, OPXA and AGTC

 

CAPR is up again +$0.93 after Monday’s +$0.32) on a press release of October’s data release – wait for the erosion! Icarus flew high and crashed into the sea!

Lighting the stock price on fire was: ONCE again, KITE, STML, ATHX and even FCSC JUNO with a few others …

BLFS who was down -$0.14 after Monday’s +$0.44 to $5.29 – something is up as volume is huge, 947.8 K shares traded <3 month average = 141.02 K shares> - it better happen soon like an offering to raise cash and not live on debt or are they preparing for a take-out after 12/31/16’s price of $1.61 … or as I stated yesterday, is there a strategy here or will an Icarus flight pattern be readied?

 

 

Pre-open indications: 6 hits and 1 miss:

  • AxoGen (AXGN) closed down -$0.25 – hit;
  • BioLife Solutions (BLFS) closed down -$0.16 – hit;
  • Bellicum Pharmaceuticals (BLCM) closed down -$0.04 – miss;
  • blue bird bio (BLUE) closed down -$2.75 – hit;
  • Cellectis SA (CLLS) closed down -$0.49 – hit;
  • Juno Therapeutics (JUNO) closed down -$0.85 – hit;
  • Regenxbio (RGNX) closed down -$0.75 – hit;

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The first hour was neutral with an A/DL of 20/20 and 3 flats;

·         The mid-day was barely positive  with an A/DL of 21/19 and 3 flat;

·         The close was negative with an A/DL of 19/21 and 3 flat;

 

 

Out and about:

ETFs with exposure to Applied Genetic Technologies Corp …

Comparing the performance and risk of Applied Genetic Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. These ETFs may not have the highest percentage of Applied Genetic Technologies Corp., but offer a broader sector/region exposure

Here are 5 ETFs with the largest exposure to AGTC.

 

Ticker    Fund Name        AGTC-US Exposure (%) 1 Year Price Performance (%)    1 Year Volatility (%)       Net Expense Ratio (%)         Number of Holdings

WMCR-US          Wilshire Micro-Cap ETF                0.05        18.74     11.99     0.59        799

IWC-US                iShares Micro-Cap ETF   0.02        18.19     14.37     0.6          1393

EES-US  WisdomTree SmallCap Earnings Fund    0.01        19.64     14.14     0.38        786

VXF-US Vanguard Extended Market ETF                0              16.77     11.34     0.08        3186

VUS-CN                Vanguard US Total Market Index ETF CAD Hedged           0              17.65     8.41 0.15              3526

AGTC-US             Applied Genetic Technologies Corp.      100         -57.96    1.69        0 1         

 

 

Daily analytics:

All three main U.S. stock indexes ended at all-time highs on Tuesday, as Federal Reserve policy makers began a two-day policy meeting in which they’re expected to finalize the details of their plan to begin slowly shrinking the central bank’s $4.5 trillion balance sheet.

·         The Dow rose 39.45 points, or 0.2%, to close at 22,370.80, extending its win streak to eight sessions and notching its 41st record close of the year.

·         The S&P 500 index rose 2.78 points, or 0.1%, to 2,506.65, closing at a record for the 36th time this year. Tuesday’s gain is its sixth in the past seven sessions.

·         The NASDAQ rose 6.68 points to 6,461.32, a gain of 0.1%. The tech-heavy index set a record for the 49th time in 2017 and is currently up 20% year-to-date.

 

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Tuesday closed at 10.18, up +0.30% …

  • Monday traded at 10.15, down -0.20% after Friday traded at 10.21, down -2.30% after Thursday traded at 10.44, down -0.57% after Wednesday traded at 10.51, down -0.66% and last  Tuesday traded at 10.58, down -1.40%

 

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Tuesday was FLAT (haven’t seen that in quite a while)

·         Monday +0.70%

·         Friday +0.45%

·         Thursday -0.08%

·         Wednesday +0.30%

·         Last Tuesday+0.61%

 

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Tuesday was DOWN -0.67%

·         Monday +0.11%

·         Friday -0.07%

·         Thursday -0.59%

·         Wednesday -0.33%

·         Last Tuesday +0.22%

 

 

The count - decliners versus gainers:

……. look at the differences in the spreads as decliners jump and %

·         Tuesday’s decliners ranged from -0.31% <BLCM -$0.04> to -3.73% <MDXG -$0.51> in 21 equities;

·         Monday’s decliners ranged from -0.36% <BSTG -$0.0012> to -6.13% <ONVO -$0.13> in 11 equities;

·         Friday’s decliners ranged from -0.19% <BLUE -$0.25> to -6.19% <ONVO -$0.14> in 19 equities;

·         Thursday’s decliners ranged from -1.20% <CYTX -$0.0042> to -4.74% <XON -$0.94> in 22 equities;

·         Wednesday’s decliners ranged from -0.27% <AXGN -$0.05> to -18.18% <AGTC -$0.90> in 15 equities;

·         Last Tuesday’s decliners ranged from -0.06% <KITE -$0.11> to -3.91% <PSTI -$0.05> in 27 equities;

Versus

… Look at the percentage’s (%) and spreads …

·         Tuesday’s gainers ranged from +0.26% <CLBS +$0.01> to +70.45% <CAPR +$0.93> in 19 equities;

·         Monday’s gainers ranged from +0.16% <KITE +$0.28> to +32% <CAPR +$0.32> in 28 equities;

·         Friday’s gainers ranged from +0.66% <ONCE +$0.54> to +8.52% <BLCM +$0.92> in 23 equities;

·         Thursday’s gainers ranged from +0.21% <BLFS +$0.01> to +4.39% <BLUE +$5.55> in 20 equities;

·         Wednesday’s gainers ranged from +0.10% <XON +$0.02> to +9.76% <PSTI +$0.12> in 27 equities;

·         Last Tuesday’s gainers ranged from +0.17% <OSIR +$0.01> to +5.32% <AGTC +$0.25> in 14 equities;

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.